South Korea Cancer Immunotherapy Market Report by Therapy Type (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators, and Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, and Others), End User (Hospitals, Cancer Research Centers, Clinics, and Others), and Region 2026-2034
South Korea cancer immunotherapy market size reached USD 2.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.4 Billion by 2034, exhibiting a growth rate (CAGR) of 7.79% during 2026-2034.The growing scientific breakthroughs in understanding the complexities of the immune system, rising prevalence of cancer cases among the masses due to the adoption of unhealthy lifestyle, and increasing identification of specific biomarkers represent some of the key factors driving the market.
Cancer immunotherapy, also known as immuno-oncology, is a comprehensive approach to treating cancer that harnesses the immune system of the body to recognize, attack, and eliminate cancer cells. It involves various checkpoint inhibitors, which target specific proteins in immune cells or cancer cells, unleashing the immune system to identify and kill malignant cells more effectively. It also includes CAR-T cell therapy, which is a personalized approach where the immune cells (T cells) of the patient are genetically modified to express chimeric antigen receptors (CARs). It can be preventive, targeting viruses that can lead to cancer, or therapeutic, enhancing the immune response against existing cancer cells. It encompasses monoclonal antibodies, which are laboratory-made molecules that can mimic the ability of the immune system to fight off harmful pathogens. Cancer immunotherapy offers a more precise and targeted approach compared to traditional treatments. It has demonstrated unprecedented success in treating cancers that were once considered incurable. It offers reduced toxicity, which translates into an improved quality of life for patients taking treatment. It has shown remarkable efficacy in treating cancers that have proven resistant to conventional therapies, providing a promising avenue for patients facing limited treatment options.
SOUTH KOREA CANCER IMMUNOTHERAPY MARKET TRENDS:
At present, increasing scientific breakthroughs in understanding the complexities of the immune system and its interactions with cancer represent one of the crucial factors impelling the growth of the market in South Korea. These advancements are significantly expanding the therapeutic arsenal against various malignancies, providing clinicians with powerful tools to help the immune system in the fight against cancer. Besides this, the rising prevalence of cancer among the masses due to the adoption of unhealthy lifestyles, excessive smoking, and consumption of alcohol daily is contributing to the growth of the market in the country. In addition, the exploration of personalized medicine and biomarkers is emerging as a prominent trend, enabling a more precise and tailored approach to cancer immunotherapy. The identification of specific biomarkers helps in predicting patient responses and selecting individuals who are most likely to benefit from immunotherapeutic interventions. This personalized approach not only enhances treatment efficacy but also minimizes adverse effects, contributing to the overall acceptance and adoption of immunotherapy across diverse cancer types. Apart from this, regulatory agencies in the country are showing a commitment to expediting the approval processes for novel immunotherapies, recognizing their potential to address unmet medical needs. Fast-track designations, breakthrough therapy designations, and accelerated approval pathways are becoming integral components of regulatory frameworks, facilitating a more streamlined and rapid route to market for promising immunotherapeutic agents. Additionally, numerous healthcare systems are adapting reimbursement strategies to accommodate the unique characteristics of immunotherapies, acknowledging their long-term benefits and cost-effectiveness.
SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country levels for 2026-2034. Our report has categorized the market based on therapy type, application, and end user.
Therapy Type Insights:
Application Insights:
End User Insights:
Regional Insights:
COMPETITIVE LANDSCAPE:
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea cancer immunotherapy market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the South Korea cancer immunotherapy market?
What is the breakup of the South Korea cancer immunotherapy market on the basis of therapy type?
What is the breakup of the South Korea cancer immunotherapy market on the basis of application?
What is the breakup of the South Korea cancer immunotherapy market on the basis of end user?
What are the various stages in the value chain of the South Korea cancer immunotherapy market?
What are the key driving factors and challenges in the South Korea cancer immunotherapy?
What is the structure of the South Korea cancer immunotherapy market and who are the key players?
What is the degree of competition in the South Korea cancer immunotherapy market?
Cancer immunotherapy, also known as immuno-oncology, is a comprehensive approach to treating cancer that harnesses the immune system of the body to recognize, attack, and eliminate cancer cells. It involves various checkpoint inhibitors, which target specific proteins in immune cells or cancer cells, unleashing the immune system to identify and kill malignant cells more effectively. It also includes CAR-T cell therapy, which is a personalized approach where the immune cells (T cells) of the patient are genetically modified to express chimeric antigen receptors (CARs). It can be preventive, targeting viruses that can lead to cancer, or therapeutic, enhancing the immune response against existing cancer cells. It encompasses monoclonal antibodies, which are laboratory-made molecules that can mimic the ability of the immune system to fight off harmful pathogens. Cancer immunotherapy offers a more precise and targeted approach compared to traditional treatments. It has demonstrated unprecedented success in treating cancers that were once considered incurable. It offers reduced toxicity, which translates into an improved quality of life for patients taking treatment. It has shown remarkable efficacy in treating cancers that have proven resistant to conventional therapies, providing a promising avenue for patients facing limited treatment options.
SOUTH KOREA CANCER IMMUNOTHERAPY MARKET TRENDS:
At present, increasing scientific breakthroughs in understanding the complexities of the immune system and its interactions with cancer represent one of the crucial factors impelling the growth of the market in South Korea. These advancements are significantly expanding the therapeutic arsenal against various malignancies, providing clinicians with powerful tools to help the immune system in the fight against cancer. Besides this, the rising prevalence of cancer among the masses due to the adoption of unhealthy lifestyles, excessive smoking, and consumption of alcohol daily is contributing to the growth of the market in the country. In addition, the exploration of personalized medicine and biomarkers is emerging as a prominent trend, enabling a more precise and tailored approach to cancer immunotherapy. The identification of specific biomarkers helps in predicting patient responses and selecting individuals who are most likely to benefit from immunotherapeutic interventions. This personalized approach not only enhances treatment efficacy but also minimizes adverse effects, contributing to the overall acceptance and adoption of immunotherapy across diverse cancer types. Apart from this, regulatory agencies in the country are showing a commitment to expediting the approval processes for novel immunotherapies, recognizing their potential to address unmet medical needs. Fast-track designations, breakthrough therapy designations, and accelerated approval pathways are becoming integral components of regulatory frameworks, facilitating a more streamlined and rapid route to market for promising immunotherapeutic agents. Additionally, numerous healthcare systems are adapting reimbursement strategies to accommodate the unique characteristics of immunotherapies, acknowledging their long-term benefits and cost-effectiveness.
SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country levels for 2026-2034. Our report has categorized the market based on therapy type, application, and end user.
Therapy Type Insights:
- Monoclonal Antibodies
- Cancer Vaccines
- Checkpoint Inhibitors
- Immunomodulators
- Others
Application Insights:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Others
End User Insights:
- Hospitals
- Cancer Research Centers
- Clinics
- Others
Regional Insights:
- Seoul Capital Area
- Yeongnam (Southeastern Region)
- Honam (Southwestern Region)
- Hoseo (Central Region)
- Others
COMPETITIVE LANDSCAPE:
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea cancer immunotherapy market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the South Korea cancer immunotherapy market?
What is the breakup of the South Korea cancer immunotherapy market on the basis of therapy type?
What is the breakup of the South Korea cancer immunotherapy market on the basis of application?
What is the breakup of the South Korea cancer immunotherapy market on the basis of end user?
What are the various stages in the value chain of the South Korea cancer immunotherapy market?
What are the key driving factors and challenges in the South Korea cancer immunotherapy?
What is the structure of the South Korea cancer immunotherapy market and who are the key players?
What is the degree of competition in the South Korea cancer immunotherapy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - INTRODUCTION
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET LANDSCAPE
5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)
6 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - BREAKUP BY THERAPY TYPE
6.1 Monoclonal Antibodies
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2020-2025)
6.1.3 Market Forecast (2026-2034)
6.2 Cancer Vaccines
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2020-2025)
6.2.3 Market Forecast (2026-2034)
6.3 Checkpoint Inhibitors
6.3.1 Overview
6.3.2 Historical and Current Market Trends (2020-2025)
6.3.3 Market Forecast (2026-2034)
6.4 Immunomodulators
6.4.1 Overview
6.4.2 Historical and Current Market Trends (2020-2025)
6.4.3 Market Forecast (2026-2034)
6.5 Others
6.5.1 Historical and Current Market Trends (2020-2025)
6.5.2 Market Forecast (2026-2034)
7 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - BREAKUP BY APPLICATION
7.1 Lung Cancer
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2020-2025)
7.1.3 Market Forecast (2026-2034)
7.2 Breast Cancer
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2020-2025)
7.2.3 Market Forecast (2026-2034)
7.3 Colorectal Cancer
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2020-2025)
7.3.3 Market Forecast (2026-2034)
7.4 Melanoma
7.4.1 Overview
7.4.2 Historical and Current Market Trends (2020-2025)
7.4.3 Market Forecast (2026-2034)
7.5 Prostate Cancer
7.5.1 Overview
7.5.2 Historical and Current Market Trends (2020-2025)
7.5.3 Market Forecast (2026-2034)
7.6 Head and Neck Cancer
7.6.1 Overview
7.6.2 Historical and Current Market Trends (2020-2025)
7.6.3 Market Forecast (2026-2034)
7.7 Others
7.7.1 Historical and Current Market Trends (2020-2025)
7.7.2 Market Forecast (2026-2034)
8 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - BREAKUP BY END USER
8.1 Hospitals
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2020-2025)
8.1.3 Market Forecast (2026-2034)
8.2 Cancer Research Centers
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2020-2025)
8.2.3 Market Forecast (2026-2034)
8.3 Clinics
8.3.1 Overview
8.3.2 Historical and Current Market Trends (2020-2025)
8.3.3 Market Forecast (2026-2034)
8.4 Others
8.4.1 Historical and Current Market Trends (2020-2025)
8.4.2 Market Forecast (2026-2034)
9 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET – BREAKUP BY REGION
9.1 Seoul Capital Area
9.1.1 Overview
9.1.2 Historical and Current Market Trends (2020-2025)
9.1.3 Market Breakup by Therapy Type
9.1.4 Market Breakup by Application
9.1.5 Market Breakup by End User
9.1.6 Key Players
9.1.7 Market Forecast (2026-2034)
9.2 Yeongnam (Southeastern Region)
9.2.1 Overview
9.2.2 Historical and Current Market Trends (2020-2025)
9.2.3 Market Breakup by Therapy Type
9.2.4 Market Breakup by Application
9.2.5 Market Breakup by End User
9.2.6 Key Players
9.2.7 Market Forecast (2026-2034)
9.3 Honam (Southwestern Region)
9.3.1 Overview
9.3.2 Historical and Current Market Trends (2020-2025)
9.3.3 Market Breakup by Therapy Type
9.3.4 Market Breakup by Application
9.3.5 Market Breakup by End User
9.3.6 Key Players
9.3.7 Market Forecast (2026-2034)
9.4 Hoseo (Central Region)
9.4.1 Overview
9.4.2 Historical and Current Market Trends (2020-2025)
9.4.3 Market Breakup by Therapy Type
9.4.4 Market Breakup by Application
9.4.5 Market Breakup by End User
9.4.6 Key Players
9.4.7 Market Forecast (2026-2034)
9.5 Others
9.5.1 Historical and Current Market Trends (2020-2025)
9.5.2 Market Forecast (2026-2034)
10 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET – COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant
11 PROFILES OF KEY PLAYERS
11.1 Company A
11.1.1 Business Overview
11.1.2 Product Portfolio
11.1.3 Business Strategies
11.1.4 SWOT Analysis
11.1.5 Major News and Events
11.2 Company B
11.2.1 Business Overview
11.2.2 Product Portfolio
11.2.3 Business Strategies
11.2.4 SWOT Analysis
11.2.5 Major News and Events
11.3 Company C
11.3.1 Business Overview
11.3.2 Product Portfolio
11.3.3 Business Strategies
11.3.4 SWOT Analysis
11.3.5 Major News and Events
11.4 Company D
11.4.1 Business Overview
11.4.2 Product Portfolio
11.4.3 Business Strategies
11.4.4 SWOT Analysis
11.4.5 Major News and Events
11.5 Company E
11.5.1 Business Overview
11.5.2 Product Portfolio
11.5.3 Business Strategies
11.5.4 SWOT Analysis
11.5.5 Major News and Events
12 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - INDUSTRY ANALYSIS
12.1 Drivers, Restraints, and Opportunities
12.1.1 Overview
12.1.2 Drivers
12.1.3 Restraints
12.1.4 Opportunities
12.2 Porters Five Forces Analysis
12.2.1 Overview
12.2.2 Bargaining Power of Buyers
12.2.3 Bargaining Power of Suppliers
12.2.4 Degree of Competition
12.2.5 Threat of New Entrants
12.2.6 Threat of Substitutes
12.3 Value Chain Analysis
13 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - INTRODUCTION
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET LANDSCAPE
5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)
6 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - BREAKUP BY THERAPY TYPE
6.1 Monoclonal Antibodies
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2020-2025)
6.1.3 Market Forecast (2026-2034)
6.2 Cancer Vaccines
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2020-2025)
6.2.3 Market Forecast (2026-2034)
6.3 Checkpoint Inhibitors
6.3.1 Overview
6.3.2 Historical and Current Market Trends (2020-2025)
6.3.3 Market Forecast (2026-2034)
6.4 Immunomodulators
6.4.1 Overview
6.4.2 Historical and Current Market Trends (2020-2025)
6.4.3 Market Forecast (2026-2034)
6.5 Others
6.5.1 Historical and Current Market Trends (2020-2025)
6.5.2 Market Forecast (2026-2034)
7 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - BREAKUP BY APPLICATION
7.1 Lung Cancer
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2020-2025)
7.1.3 Market Forecast (2026-2034)
7.2 Breast Cancer
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2020-2025)
7.2.3 Market Forecast (2026-2034)
7.3 Colorectal Cancer
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2020-2025)
7.3.3 Market Forecast (2026-2034)
7.4 Melanoma
7.4.1 Overview
7.4.2 Historical and Current Market Trends (2020-2025)
7.4.3 Market Forecast (2026-2034)
7.5 Prostate Cancer
7.5.1 Overview
7.5.2 Historical and Current Market Trends (2020-2025)
7.5.3 Market Forecast (2026-2034)
7.6 Head and Neck Cancer
7.6.1 Overview
7.6.2 Historical and Current Market Trends (2020-2025)
7.6.3 Market Forecast (2026-2034)
7.7 Others
7.7.1 Historical and Current Market Trends (2020-2025)
7.7.2 Market Forecast (2026-2034)
8 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - BREAKUP BY END USER
8.1 Hospitals
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2020-2025)
8.1.3 Market Forecast (2026-2034)
8.2 Cancer Research Centers
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2020-2025)
8.2.3 Market Forecast (2026-2034)
8.3 Clinics
8.3.1 Overview
8.3.2 Historical and Current Market Trends (2020-2025)
8.3.3 Market Forecast (2026-2034)
8.4 Others
8.4.1 Historical and Current Market Trends (2020-2025)
8.4.2 Market Forecast (2026-2034)
9 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET – BREAKUP BY REGION
9.1 Seoul Capital Area
9.1.1 Overview
9.1.2 Historical and Current Market Trends (2020-2025)
9.1.3 Market Breakup by Therapy Type
9.1.4 Market Breakup by Application
9.1.5 Market Breakup by End User
9.1.6 Key Players
9.1.7 Market Forecast (2026-2034)
9.2 Yeongnam (Southeastern Region)
9.2.1 Overview
9.2.2 Historical and Current Market Trends (2020-2025)
9.2.3 Market Breakup by Therapy Type
9.2.4 Market Breakup by Application
9.2.5 Market Breakup by End User
9.2.6 Key Players
9.2.7 Market Forecast (2026-2034)
9.3 Honam (Southwestern Region)
9.3.1 Overview
9.3.2 Historical and Current Market Trends (2020-2025)
9.3.3 Market Breakup by Therapy Type
9.3.4 Market Breakup by Application
9.3.5 Market Breakup by End User
9.3.6 Key Players
9.3.7 Market Forecast (2026-2034)
9.4 Hoseo (Central Region)
9.4.1 Overview
9.4.2 Historical and Current Market Trends (2020-2025)
9.4.3 Market Breakup by Therapy Type
9.4.4 Market Breakup by Application
9.4.5 Market Breakup by End User
9.4.6 Key Players
9.4.7 Market Forecast (2026-2034)
9.5 Others
9.5.1 Historical and Current Market Trends (2020-2025)
9.5.2 Market Forecast (2026-2034)
10 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET – COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant
11 PROFILES OF KEY PLAYERS
11.1 Company A
11.1.1 Business Overview
11.1.2 Product Portfolio
11.1.3 Business Strategies
11.1.4 SWOT Analysis
11.1.5 Major News and Events
11.2 Company B
11.2.1 Business Overview
11.2.2 Product Portfolio
11.2.3 Business Strategies
11.2.4 SWOT Analysis
11.2.5 Major News and Events
11.3 Company C
11.3.1 Business Overview
11.3.2 Product Portfolio
11.3.3 Business Strategies
11.3.4 SWOT Analysis
11.3.5 Major News and Events
11.4 Company D
11.4.1 Business Overview
11.4.2 Product Portfolio
11.4.3 Business Strategies
11.4.4 SWOT Analysis
11.4.5 Major News and Events
11.5 Company E
11.5.1 Business Overview
11.5.2 Product Portfolio
11.5.3 Business Strategies
11.5.4 SWOT Analysis
11.5.5 Major News and Events
12 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET - INDUSTRY ANALYSIS
12.1 Drivers, Restraints, and Opportunities
12.1.1 Overview
12.1.2 Drivers
12.1.3 Restraints
12.1.4 Opportunities
12.2 Porters Five Forces Analysis
12.2.1 Overview
12.2.2 Bargaining Power of Buyers
12.2.3 Bargaining Power of Suppliers
12.2.4 Degree of Competition
12.2.5 Threat of New Entrants
12.2.6 Threat of Substitutes
12.3 Value Chain Analysis
13 APPENDIX
